[EN] N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] DÉRIVÉS DE PHÉNYL BIGUANIDE À SUBSTITUTION N1-AMINE CYCLIQUE-N5, PROCÉDÉS DE PRÉPARATION ASSOCIÉS ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
申请人:HANALL BIOPHARMA CO LTD
公开号:WO2013022278A3
公开(公告)日:2013-04-25
N1-CYCLIC AMINE-N5-SUBSTITUTED PHENYL BIGUANIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
申请人:Immunomet Therapeutics Inc.
公开号:EP2742019B1
公开(公告)日:2021-03-03
PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, OR COMBINATION THEREOF, AND METHOD FOR USING SAME
申请人:INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
公开号:US20200038347A1
公开(公告)日:2020-02-06
Provided are a pharmaceutical composition for preventing or treating inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof, the pharmaceutical composition including a compound represented by Formula 1, or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a method using the pharmaceutical composition. The pharmaceutical composition and the method can be used to effectively prevent or treat inflammatory disease, autoimmune disease, graft rejection responses, or combinations thereof.
US9540325B2
申请人:——
公开号:US9540325B2
公开(公告)日:2017-01-10
N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same
申请人:Kim Sung Wuk
公开号:US20140179660A1
公开(公告)日:2014-06-26
An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.